Wayne, PA - The FDA has approved a new antihypertensive, Atacand HCT?, a combination of the angiotensin II receptor blocker candesartan cilexetil (Atacand®) and the diuretic hydrochlorothiazide, both of which have been previously approved, the drug's manufacturer, AstraZeneca, announced.
Atacand HCT, available in two combinations, 32 mg candesartan cilexetil - 12.5 mg hydrochlorothiazide, and 16 mg candesartan cilexetil - 12.5 mg hydrochlorothiazide, is indicated for second-line treatment of hypertension as another treatment option for patients unable to control their blood pressure with a single agent, the company said.
Heartwire from Medscape © 2000
Cite this: FDA approves new combination antihypertensive - Medscape - Sep 07, 2000.
Comments